Evidence map›Paper›PMID 36839751›Full record

ArticlePharmaceutics2023

Encapsulation of SAAP-148 in Octenyl Succinic Anhydride-Modified Hyaluronic Acid Nanogels for Treatment of Skin Wound Infections.

Miriam E van Gent, Tom van Baaren, Sylvia N Kłodzińska, Muhanad Ali, Natasja Dolezal, Bjorn R van Doodewaerd, Erik Bos, Amy M de Waal, Roman I Koning, Jan Wouter Drijfhout and 2 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Miriam E van GentDepartment of Infectious Diseases, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.ORCID 0000-0002-9751-0650
Tom van BaarenDepartment of Infectious Diseases, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Sylvia N KłodzińskaCenter for Biopharmaceuticals and Biobarriers in Drug Delivery (BioDelivery), Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Muhanad AliDepartment of Infectious Diseases, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Natasja DolezalDepartment of Immunology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Bjorn R van DoodewaerdDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.ORCID 0000-0001-9528-5587
Erik BosElectron Microscopy Facility, Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Amy M de WaalDepartment of Infectious Diseases, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Roman I KoningElectron Microscopy Facility, Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.ORCID 0000-0001-6736-7147
Jan Wouter DrijfhoutDepartment of Immunology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Hanne Mørck NielsenCenter for Biopharmaceuticals and Biobarriers in Drug Delivery (BioDelivery), Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-7285-9100
Peter H NibberingDepartment of Infectious Diseases, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Leiden University Medical Center · NLUniversity of Copenhagen · DK

Funding

Dutch Research Council 16434Novo Nordisk Foundation NNF16OC0021948
6 · The paper itself

Abstract

Chronic wound infections colonized by bacteria are becoming more difficult to treat with current antibiotics due to the development of antimicrobial resistance (AMR) as well as biofilm and persister cell formation. Synthetic antibacterial and antibiofilm peptide (SAAP)-148 is an excellent alternative for treatment of such infections but suffers from limitations related to its cationic peptidic nature and thus instability and possible cytotoxicity, resulting in a narrow therapeutic window. Here, we evaluated SAAP-148 encapsulation in nanogels composed of octenyl succinic anhydride (OSA)-modified hyaluronic acid (HA) to circumvent these limitations. SAAP-148 was efficiently (>98%) encapsulated with high drug loading (23%), resulting in monodispersed anionic OSA-HA nanogels with sizes ranging 204-253 nm. Nanogel lyophilization in presence of polyvinyl alcohol maintained their sizes and morphology. SAAP-148 was sustainedly released from lyophilized nanogels (37-41% in 72 h) upon reconstitution. Lyophilized SAAP-148-loaded nanogels showed similar antimicrobial activity as SAAP-148 against planktonic and biofilm-residing AMR

Indexed as

AMP formulationantimicrobial peptidecutaneous applicationhyaluronic acid-based nanogelsSAAP-148skin wound infections

Identifiers

PMID36839751
PMCPMC9967827
OpenAlexW4318480164

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.